By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Bristol-Myers Squibb Company 

345 Park Avenue

New York  New York  10154  U.S.A.
Phone: 212-546-4000 Fax: 212-546-4020


SEARCH JOBS

Bristol-Myers Squibb is a global BioPharma company firmly focused on its mission to discover, develop and deliver innovative medicines to patients with serious diseases.

YEAR FOUNDED:

1858

LEADERSHIP:

Founder: Edward Robinson Squibb

CEO: Giovanni Caforio, MD

CFO: Charles Bancroft

CLINICAL TRIAL:

Please click here for clinical trial information.

JOB OPPORTUNITY:

Please click here for Bristol-Myers Squibb job opportunities.

PRODUCTS:

Please click here to see all products.

For more information, visit
www.bms.com and follow us on www.twitter.com/BMSNEWS.

FOLLOW BRISTOL-MYERS SQUIBB:





Key Statistics


Email:
Ownership: Public

Web Site: Bristol-Myers Squibb
Employees:
Symbol: BMY
 





Collaborations

Gilead 

PanVera LLC 

Pharmagene Laboratories Limited 

Johnson & Johnson 

Amersham Biosciences 

Lexicon Genetics Incorporated 

Athersys  Athersys will provide Bristol-Myers Squibb with cell lines expressing validated drug targets produced using the RAGE-Validated Target technology. BMS plans to use its combinatorial chemistry capabilities to develop small molecule drug candidates against the validated targets.

Merck & Co.  Diabetes

Affinimark Technologies Inc. 

GlaxoSmithKline (North Carolina) 

Medarex, Inc. 

Gilead (Durham, NC) 

Phyton Biotech  - Cancer

Gilead (Seattle, WA) 





Company News
New FDA Report Cites 22 Drugs That Passed Phase II But Crashed and Burned in Phase III 1/20/2017 5:42:12 AM
Bristol-Myers Squibb (BMY) Release: Company Falls Behind Rival Merck & Co. (MRK), Will Not Pursue Faster Approval for Lung Cancer Combo 1/20/2017 5:29:41 AM
Bristol-Myers Squibb (BMY) Release: Company's Opdivo (Nivolumab) Demonstrated Efficacy And Improved Survival In Patients With Previously Treated Advanced Gastric Cancer In A Randomized Phase III Study 1/19/2017 7:28:29 AM
Why Bristol-Myers Squibb (BMY) Could be a Takeover Target Soon 1/17/2017 8:45:11 AM
Bristol-Myers Squibb (BMY) And GeneCentric Diagnostics Announce Exploratory Biomarker Research Collaboration 1/6/2017 11:15:30 AM
Janssen Biotech (JNJ) Enters Immunotherapy Clinical Collaboration With Bristol-Myers Squibb (BMY) To Evaluate Daratumumab (DARZALEX) In Combination With Nivolumab (OPDIVO) 1/5/2017 6:21:11 AM
3 Of The Biggest Risks For Bristol-Myers Squibb (BMY) In 2017 1/3/2017 6:08:17 AM
Bristol-Myers Squibb (BMY) And Calithera Biosciences (CALA) Announce Clinical Collaboration To Evaluate Opdivo (Nivolumab) In Combination With CB-839 In Clear Cell Renal Cell Carcinoma 12/21/2016 12:58:59 PM
Giovanni Caforio Named Chairman Of Bristol-Myers Squibb (BMY)’s Board Of Directors 12/21/2016 12:00:35 PM
Bristol-Myers Squibb (BMY) Inks $936 Million “Armed” Oncolytic Virus Deal With PsiOxus 12/20/2016 6:37:27 AM
12345678910...
//-->